Endpoints News
MapLight undeterred by Phase 2 autism failure Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
Mon T W Th F
22 June, 2026
Advising. Financing. Global Strategy.
Stay Current on Healthcare Equity Markets, M&A, and Venture Financing
sponsored by DNB Carnegie/Back Bay
top stories
1. Merck's IBD drug from $10.8B Prometheus deal claims its first Phase 3 win
2. MapLight to discuss future of autism drug with FDA despite Phase 2 disappointment
3. Live at 12 p.m. today: Are the China hawks winning?
4.
news briefing
Lilly allies with BioArctic; Antengene and Insilico sign deals
5. AbbVie makes $10.9B move for Apogee's long-acting I&I drug candidates
6. Sanofi R&D leader Houman Ashrafian to depart, Paulo Fontoura to take the reins
7. Definium reports Phase 3 hit for LSD drug in severe form of depression
8. Regenxbio to resubmit Hunter syndrome gene therapy as FDA rare disease about-face continues
9. Bionyra's $165M launch: A Sanofi alum, I&I candidates from China, one big catch-up
10. Nura Bio gets $73.8M to advance SARM1 inhibitors for neurodegeneration
11. FDA vaccine advisors back Moderna’s flu vaccine, bucking past FDA leadership
more stories
• 
Karen Weintraub
.

Merck bought Prometheus in 2023 for $10.8 billion. New results from a Phase 3 in IBD start to justify that payout. And if you’re at BIO this week, say hello to Endpoints reporters Max Bayer, Ryan Cross, Andrew Dunn and Kyle LaHucik.
.
Karen Weintraub
Deputy Editor, Endpoints News
1
by Max Gelman

Mer­ck’s $10.8 bil­lion buy­out of Prometheus Bio­sciences is show­ing its first signs of pay­ing off.

The lead pro­gram of that ac­qui­si­tion suc­ceed­ed in its first...

Read the full story
2
by Ayisha Sharma

Map­Light Ther­a­peu­tics is hold­ing to hope that there's a path for­ward for its autism drug de­spite the pro­gram flunk­ing a mid-stage study.

The biotech’s treat­ment...

Read the full story
3
by Drew Armstrong

I don't know who will win the de­bate on Chi­na biotech in Wash­ing­ton, but I do know which voic­es are the loud­est.

Over the past...

Read the full story
The Endpoints 100: Despite all the turmoil, biotech is having a moment
A year ago, biotech was in its bleakest stretch in a decade. Now IPOs are rebounding and China deals are heating up. John Carroll and a panel of industry leaders dig into the latest Endpoints 100 results and uncover what’s next for the sector.
News Briefing: Quick hits from the biopharma web
4
by ENDPOINTS

Plus news about De­nali, Nu­vec­tis Phar­ma, Graph Ther­a­peu­tics, Gon­do­laBio and the No­vo Nordisk Foun­da­tion. 

🔗 Eli Lil­ly’s al­liance with BioArc­tic: The In­di­anapo­lis drug gi­ant will...

Read the full story
Apogee Therapeutics CEO Michael Henderson
5
by Kyle LaHucik

Ab­b­Vie is mak­ing its largest post-Al­ler­gan ac­qui­si­tion in a $10.9 bil­lion move for im­munol­o­gy biotech Apogee Ther­a­peu­tics.

Apogee's long-act­ing IL-13 drug, called zu­milok­ibart, is slat­ed...